10-K Filing: CNBX Pharmaceuticals Inc. submits SEC annual report
CNBX Pharmaceuticals Inc. recently submitted its annual report Form 10-K to the Securities and Exchange Commission. The filing, dated August 31, 2024, provides detailed information about the company’s financial performance and operations over the past year. With a mailing address at #3 Bethesda Metro Center, Suite 700, Bethesda, MD 20814, and a business phone number of 877-424-2429, CNBX Pharmaceuticals Inc. is a pharmaceutical company focused on the development and commercialization of innovative treatments.
The filing includes several attachments, such as the Form 10-K for August 2024, certifications, and graphic images related to the report. You can access these documents using the following links:
– FORM 10-K FOR AUGUST 2024
– CERTIFICATION 1
– CERTIFICATION 2
In addition to these documents, the filing also contains XBRL data files, including a schema file, calculation file, definition file, label file, presentation file, and an extracted XBRL instance document. These files provide structured data about the company’s financial information, making it easier for investors and analysts to analyze the data.
CNBX Pharmaceuticals Inc. operates in the pharmaceutical preparations industry with a focus on developing innovative treatment options for patients. As a publicly traded company, it is required to submit annual reports and other filings to the SEC to provide transparency and accountability to its stakeholders.
For more information about CNBX Pharmaceuticals Inc. and to access the complete submission text file, you can visit their [website](#) or view the original filing here.
